This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered In-Person & Digitally
March 28–30, 2022, Basel, SwitzerlandApril 4–6, 2022, Digital Partnering

GAOMA Therapeutics

Profile

GAOMA develops new therapeutic molecules, with a particular focus on epilepsy and cognitive disorders. GAO-3-02 is a novel patented active ingredient, with an innovative MoA for the treatment of epilepsy. In various preclinical PoC studies, it demonstrated its ability to limit seizures but also to protect/restore cognitive functions, both on the long term. The company will also rapidly explore the interest of GAO-3-02 in other indications.